Note: The coverage figure is the manufacturer's statement, as captured on November 14, 2026. The line carries no reference marker; the page's reference list cites Novartis data on file (LEQVIO Coverage and Affordability, 2025).
Note: The figure appears under the traditional Medicare tab of the affordability page, as captured on November 14, 2026. The line carries no reference marker; the page's reference list cites Novartis data on file (LEQVIO Coverage and Affordability, 2025). The LEQVIO Co-pay Program is not valid under Medicare.
Note: The statement is as captured on November 14, 2026. The line carries no reference marker; the page's reference list cites Novartis data on file (LEQVIO Coverage and Affordability, 2025). The LEQVIO Co-pay Program is not valid under Medicaid.
How much do commercially insured patients pay for Leqvio?
Note: The two figures describe different groups and data sets, both as captured on November 14, 2026: patients who used the LEQVIO Co-pay Program (patient support page, citing Novartis data on file, 2024) and commercial patients (affordability page; the line carries no reference marker, and the page's reference list cites Novartis data on file, 2025). The co-pay program is valid only for patients with commercial insurance, and per-treatment maximums and an annual benefit cap apply.
Note: The two manufacturer sources differ. The affordability page states, under its Medicare tab, which describes traditional Medicare, that no prior authorization is required for all Medicare patients (as captured on November 14, 2026). The Buy-and-Bill 5-Step Guide states that patients with traditional Medicare will likely not require prior authorization and that patients with Medicare Advantage or commercial insurance may need to submit one.
What prior authorization criteria do plans use for Leqvio?